pneumonia after BMT. [3] [4] [5] Nevertheless, even today, CMV interstitial pneumonia remains a serious complication of BMT with a high mortality rate. The presence of CMV in A comparative cytomegalovirus (CMV) diagnostic study was carried out on 30 bone marrow transplant patients. bronchoalveolar lavage fluid (BALF) during the recovery period after BMT is considered to be a risk factor for CMV Forty-three bronchoalveolar lavage fluid (BALF) samples from these patients were examined for CMV pneumonia. 6,7 However, testing for CMV antigenemia is, compared with collection of BALF, totally noninvasive. Thirty patients who underwent BMT from a related or unremia assay was inferior to the sensitive tests of BALF lated donor at Tokyo Metropolitan Komagome General samples, statistically significant correlations were demHospital between February 1993 and September 1994 were onstrated between the CMV antigenemia assay, viral enrolled in this study. BAL was carried out 28 times as a culture, shell vial and cytology. Although the CMV antiscreening procedure and 15 times as a diagnostic procedure genemia assay was shown to be useful for detection of in these patients. Patient characteristics are shown in CMV, it may be necessary to confirm not only the sensi- Table 1 . tivity but also the specificity of this method for prevenFor prevention of graft-versus-host disease (GVHD) in tion of CMV disease after BMT.
144
appear brown in color, and they are easy to distinguish from negative cells. The degree of CMV antigenemia was calcuFifty milliliters of physiological saline were infused into lated as the number of CMV antigen-positive cells detected the lungs and retrieved by aspiration. This procedure was in 5 × 10 4 leukocytes. performed three times. The resultant BALF was employed for subsequent studies which have been previously described.
7,10

Administration of ganciclovir
Ganciclovir was given to patients whose samples from the Culture screening BAL were positive for CMV by shell vial as Retrieved BALF was inoculated on to MRC-5 cells and described elsewhere. 6 The clinical courses of the patients incubated for a maximum of 2 months. 11 If a cytopathic whose BALF samples were positive only by PCR were effect was observed, the pathogen was scrutinized for CMV carefully monitored without ganciclovir administration. The positivity by immunofluorescence. patient who developed CMV pneumonia was treated with ganciclovir and CMV-specific immune globulin. 4 Cytology Statistics BALF was centrifuged on to the slide glasses by cytospin and stained with Papanicolaou's stain. Cells in the speciFor comparison of CMV-positive rates obtained with each mens were then inspected for the presence of typical of the CMV detection tests used on BALF samples and the inclusion bodies in the nucleus.
CMV antigenemia assay, results of the BALF tests and the CMV antigenemia assay were required to both be positive or both be negative. For these cases, the percentage of Rapid centrifugal culture agreement was calculated. Cohen's coefficients of agreeRapid centrifugal culture, conventionally referred to as the ment were also calculated, which takes into consideration 'shell vial' test was peformed following the method of cases where results were not in agreement. Statistical testCleaves et al.
12 BALF samples were inoculated on to cells ing was carried out individually for each of the 43 BALF (MRC-5) cultured on round coverslips, followed by centrisamples. fugation and culture for 24 h. Cultured cells were then tested for presence of CMV antigen by the indirect fluorescent antibody technique, employing an anti-CMV monoResults clonal antibody (72 kDa; Dupont, Wilmington, DE, USA).
Detection of CMV in BALF Polymerase chain reaction (PCR)
Out of 43 BALs on the 30 post-BMT patients, CMV was detected in 12 BALF samples from nine patients. A positive PCR was carried out according to the method of Olive et al. 13 DNA was extracted from BALF cells using the Isoresult was obtained from 10 samples by viral culture, 10 samples by PCR, eight samples by shell vial and three were both negative for 31 samples. These two tests gave conflicting results for eight BALF samples: six samples samples by cytology (Table 2) . Of the 12 BALF samples which gave positive results for CMV detection in at least were positive by viral culture but negative by CMV antigenemia assay, while two samples were positive by CMV one of the tests, eight samples were positive by three or more of the tests, two samples were positive by two tests antigenemia assay but negative by viral culture. Similarly, results of the CMV antigenemia assay and and two samples were positive by only one test. Samples which were positive by either cytology or shell vial were PCR were in agreement in 33 of the 43 BALF samples (76.7%). That is, both the CMV antigenemia assay and also positive by either PCR or viral culture, or both. Two of the 10 positive samples were positive by PCR but nega-PCR were positive for three samples, while they were both negative for 30 samples. Contradictory results were tive by viral culture. Two samples which were positive by viral culture were negative in PCR. obtained in these two tests for 10 samples: seven samples were PCR-positive but CMV antigenemia-negative, while
CMV antigenemia assay
Of the 43 peripheral blood samples collected in parallel (81.4%). That is, both the CMV antigenemia assay and viral culture were positive for four samples, while they three samples were CMV antigenemia-positive but PCRThese findings indicate that CMV can be readily detected in BALF when the patient is positive for CMV antigenemia. negative.
Comparison of results for CMV antigenemia assay and Statistical analysis of the correlation between these findings revealed a high rate of agreement between detection of shell vial shows that they were in agreement for 37 of the 43 BALF samples (86.0%). The results were positive with CMV antigenemia and detection of CMV in BALF samples (Table 3 ). The highest agreement rate and the highest both of these tests for four samples and negative with both for 33 samples. Disagreement in the test results was seen degree of correlation were found in CMV antigenemia assays and shell vial test results. Conversely, PCR showed in six samples: four samples were shell vial-positive but CMV antigenemia-negative, and two samples were CMV the lowest correlation with CMV antigenemia, and only this combination of methods showed no statistical significance. antigenemia-positive but shell vial-negative.
Results of the CMV antigenemia assay and cytology We did not carry out a simultaneous PCR test on peripheral blood leukocytes. However, according to the reports of were in agreement for 38 of the 43 BALF samples (88.4%). That is, both the CMV antigenemia assay and cytology Schmidt et al 15 and Vlieger et al, 16 who used similar anti-CMV antibodies, the PCR and CMV antigenemia assays were positive for two samples, and they were both negative for 36 samples. The results were in disagreement for five are both sensitive. They demonstrated that although the results with these two tests showed a high level of agreesamples: one sample was positive by cytology but negative by CMV antigenemia assay, while four samples were posiment, PCR was the more sensitive of the two. In this study, BALF testing especially by PCR, virus culture and shell tive by CMV antigenemia assay but negative by cytology.
Cohen's coefficients of correlation were determined vial, was shown to be more sensitive than the CMV antigenemia assay. between the CMV antigenemia assay and each of the four CMV examination methods used in BALF samples. A statSchmidt et al 6 carried out pre-emptive therapy by administering ganciclovir to patients predicted to develop CMV istically significant positive correlation was found between the CMV antigenemia assay and each of the tests with the disease on the basis of a positive result for the shell vial test used on BALF samples, and they reported a significant exception of PCR (Table 3) .
decrease in the incidence of CMV disease. With this method, however, there were cases in which CMV pneu-CMV pneumonia monia developed at a later date when initial BALF samples had been negative for CMV; that is, there were also falseThe six patients with BALF samples positive for shell vial did not show any evidence of pneumonia and were given negative cases. In these cases, they blamed the low sensitivity of the shell vial test. In our study, there are also cases pre-emptive therapy with ganciclovir; they survived without CMV disease. During this study, only one patient (UPN (UPN107 and UPN109) in whom all of the initial test results were negative, including the CMV antigenemia 109) developed CMV pneumonia. His sample from the first screening BAL on day 34 was negative for CMV by BALF assay, but they later became positive for CMV. It is therefore surmised that false-negative test results for BALF testing and CMV antigenemia. On day 94, the clinical symptoms of pneumonia developed and CMV was detected samples are not only due to insufficient sensitivity of the test method, but also to the time when viral replication by BALF testing and CMV antigenemia assay. He died of CMV pneumonia on day 107. occurs. BAL is an unpleasant examination for patients and cannot be performed repeatedly as a surveillance examination. Non-invasive examinations such as the CMV antigenemia assay or PCR method 17 should follow BALF testDiscussion ing or replace it. Recently Boeckh et al 18 reported that CMV antigenemia-guided early treatment with ganciclovir We previously reported an evaluation and comparison of five survey methods for CMV using BALF outlining differreduced the incidence of CMV disease. However, CMV disease developed early in 8.8% of patients who were ences in sensitivity and specificity of these methods. 7 In the present study, we evaluated the use of the CMV antigeneassigned to the CMV antigenemia-guided group. Unfortunately there is not yet an ideal strategy for prevention of mia assay by comparison with examination for the presence of CMV in BALF.
CMV disease after BMT. More studies concerning the sensitivity and specificity of the CMV antigenemia assay and CMV antigen was detected in six peripheral blood cytospin samples, but only one of these samples (from UPN106, development of CMV pneumonia are needed. on day 50 post-BMT) was positive in the CMV antigenemia assay. In this case, there were no symptoms suggestive of CMV infection, and all tests conducted on BALF samples References were negative for CMV. Ganciclovir was not administered, and the clinical course of this patient was carefully moni-
